Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 34,350
-2,700 (-7.29%)
At close: Jul 28, 2026
Next Biomedical Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4,025 | 6,789 | 4,950 | 3,902 | 3,014 | 22,016 |
Short-Term Investments | 7,513 | 9,305 | 20,766 | 10,388 | 11,783 | - |
Trading Asset Securities | 22,065 | 20,904 | 15,892 | - | - | - |
Cash & Short-Term Investments | 33,603 | 36,998 | 41,609 | 14,290 | 14,797 | 22,016 |
Cash Growth | -18.94% | -11.08% | 191.17% | -3.43% | -32.79% | 226.66% |
Accounts Receivable | 3,075 | 2,236 | 1,845 | 918.64 | 314.3 | 118.67 |
Other Receivables | 108.97 | 92.97 | 321.39 | 214.28 | 170.84 | 86.52 |
Receivables | 3,184 | 2,329 | 2,167 | 1,133 | 485.15 | 205.19 |
Inventory | 2,870 | 3,036 | 2,581 | 2,169 | 1,940 | 1,313 |
Prepaid Expenses | 151.98 | 247.28 | 190.08 | 155.85 | 207.32 | 138.44 |
Other Current Assets | 1,116 | 657.75 | 341.35 | 220.7 | 90.8 | 65.69 |
Total Current Assets | 40,925 | 43,267 | 46,888 | 17,968 | 17,521 | 23,739 |
Property, Plant & Equipment | 13,944 | 14,018 | 11,270 | 11,428 | 11,735 | 11,918 |
Long-Term Investments | 3,881 | 907.78 | - | - | 2,637 | 3,737 |
Other Intangible Assets | 282.5 | 310.64 | 344.38 | 217.63 | 222.19 | 288.71 |
Long-Term Accounts Receivable | 0 | -0 | -0 | -0 | -0 | -0 |
Other Long-Term Assets | 821.91 | 761.06 | 342.75 | 29.48 | 21.35 | 37.51 |
Total Assets | 59,854 | 59,265 | 58,844 | 29,643 | 32,136 | 39,720 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 71.15 | 47.69 | 13.37 | 58.16 | 45.02 | 4.1 |
Accrued Expenses | 181.81 | 179.5 | 126.23 | 121.14 | 106.93 | 96.48 |
Short-Term Debt | 2,160 | 2,160 | 5,600 | 5,600 | 5,600 | 5,600 |
Current Portion of Long-Term Debt | 4,393 | 4,493 | 4,539 | 4,897 | 4,800 | 5,200 |
Current Portion of Leases | 38.05 | 39.84 | 26.37 | 41.51 | 35.6 | 32.24 |
Other Current Liabilities | 1,169 | 1,124 | 1,579 | 714.37 | 452.97 | 2,115 |
Total Current Liabilities | 8,013 | 8,044 | 11,884 | 11,433 | 11,041 | 13,048 |
Long-Term Debt | 774 | 950.66 | 763.5 | 933.54 | 500 | 20,873 |
Long-Term Leases | 60.41 | 68.49 | 20.58 | 46.9 | 81.63 | 46.55 |
Pension & Post-Retirement Benefits | 986.45 | 944.49 | 749.44 | 559.45 | 471.1 | 385.02 |
Other Long-Term Liabilities | 1,084 | 1,151 | 235.35 | 218.84 | 368.8 | 284.7 |
Total Liabilities | 10,919 | 11,158 | 13,653 | 13,191 | 12,462 | 34,636 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4,102 | 4,102 | 4,043 | 3,174 | 3,110 | 3,105 |
Additional Paid-In Capital | 111,130 | 111,130 | 107,234 | 61,632 | 60,679 | 60,603 |
Retained Earnings | -70,743 | -70,597 | -70,181 | -72,984 | -65,367 | -59,673 |
Comprehensive Income & Other | 4,447 | 3,472 | 4,095 | 2,277 | 1,324 | 1,049 |
Total Common Equity | 48,936 | 48,107 | 45,191 | -5,901 | -253.84 | 5,084 |
Shareholders' Equity | 48,936 | 48,107 | 45,191 | 16,452 | 19,674 | 5,084 |
Total Liabilities & Equity | 59,854 | 59,265 | 58,844 | 29,643 | 32,136 | 39,720 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 7,425 | 7,712 | 10,949 | 11,519 | 11,017 | 31,751 |
Net Cash (Debt) | 26,178 | 29,286 | 30,659 | 2,771 | 3,780 | -9,735 |
Net Cash Growth | -14.61% | -4.48% | 1006.61% | -26.70% | - | - |
Net Cash Per Share | 3209.43 | 3603.03 | 4256.48 | 441.28 | 608.67 | -2011.96 |
Filing Date Shares Outstanding | 8.2 | 8.2 | 8.09 | 6.28 | 6.21 | 4.84 |
Total Common Shares Outstanding | 8.2 | 8.2 | 8.09 | 6.28 | 6.21 | 4.84 |
Working Capital | 32,912 | 35,224 | 35,004 | 6,536 | 6,480 | 10,691 |
Book Value Per Share | 5964.97 | 5863.93 | 5588.37 | -939.89 | -40.88 | 1050.64 |
Tangible Book Value | 48,653 | 47,796 | 44,847 | -6,119 | -476.03 | 4,795 |
Tangible Book Value Per Share | 5930.54 | 5826.06 | 5545.78 | -974.55 | -76.65 | 990.97 |
Land | 5,618 | 5,618 | 5,277 | 5,277 | 5,277 | 5,277 |
Buildings | 7,318 | 7,316 | 5,786 | 5,786 | 5,786 | 5,786 |
Machinery | 2,548 | 2,566 | 1,598 | 1,430 | 1,397 | 1,504 |
Construction In Progress | 229.91 | 215.37 | 99.29 | 119.06 | 150.11 | 188.87 |